How crucial is automation of fill and finish? Considerations to overcome challenges of the final formulation, fill and finish process.
Mar
30
2021
On demand

How crucial is automation of fill and finish? Considerations to overcome challenges of the final formulation, fill and finish process.

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
     How crucial is automation of fill and finish?                                                                Considerations to overcome challenges of the final formulation, fill and finish process.

Fill and finish is a critical and high-value step in cell therapy manufacturing. At this stage, the cells have been through a tedious manufacturing process and maintaining their potency and viability through this step is of utmost importance. Currently, this step of final formulation heavily relies on manual processes that bring inherent user-dependent variability, and it becomes unsustainable with the demand for increased output in a manufacturing setting. The necessity to reduce open process steps, ensure process traceability & temperature control and minimize DMSO contact time with cells, establishes the need for automation at this step. Implementing automation at this step not only ensures a highly consistent product, it may also be an effective way to reduce risk at a critical step to support product delivery to the patients, while also reducing manufacturing costs.

In this webinar, Dalip Sethi, PhD, will discuss considerations for a closed, automated solution to fill & finish challenges.

Topics covered include:

  • Challenges in final formulation and fill step 
  • Considerations for an automated system at final formulation and fill step 
  • Data-driven Insights with automated and manual fill and finish process
Dalip Sethi
Dalip Sethi
Manager, Senior Scientist at Terumo BCT
Dalip currently serves as the scientific development lead for the Cell Therapy Technologies portfolio at Terumo BCT. He holds a doctorate degree and conducted post-doctoral studies at Thomas Jefferson University, School of Medicine. Prior to Terumo BCT, Dalip was engaged in the development of technologies & methods for use in autologous cell therapy applications. Throughout his career, Dalip has authored multiple scientific publications and is a co-inventor on several patents & patent applications.